Complete loss of EPCAM immunoexpression identifies EPCAM deletion carriers in MSH2-negative colorectal neoplasia
Autor/a
Cuatrecasas, Míriam
Gorostiaga, Iñigo
Riera, Cristina
Saperas, Esteban
Llort, Gemma
Costa, Irmgard
Matias-Guiu, Xavier
Carrato, Cristina
Navarro, Matilde
Pineda, Marta
Dueñas, Núria
Brunet, Joan
Marco, Vicente
Trias, Isabel
Busteros, José Ignacio
Mateu, Gemma
Balaguer, Francesc
Fernández-Figueras, María-Teresa
Musulén, Eva
Data de publicació
2020ISSN
2072-6694
Resum
The use of epithelial cell adhesion molecule (EPCAM) immunohistochemistry (IHC) is not included in the colorectal cancer (CRC) screening algorithm to detect Lynch syndrome (LS) patients. The aim of the present study was to demonstrate that EPCAM IHC is a useful tool to guide the LS germ-line analysis when a loss of MSH2 expression was present. We retrospectively studied MSH2 and EPCAM IHC in a large series of 190 lesions composed of malignant neoplasms (102), precursor lesions of gastrointestinal (71) and extra-gastrointestinal origin (9), and benign neoplasms (8) from different organs of 71 patients suspicious of being LS due to MSH2 alterations. LS was confirmed in 68 patients, 53 with MSH2 mutations and 15 with EPCAM 3′-end deletions. Tissue microarrays were constructed with human normal tissues and their malignant counterparts to assist in the evaluation of EPCAM staining. Among 154 MSH2-negative lesions, 17 were EPCAM-negative, including 10 CRC and 7 colorectal polyps, and 5 of them showed only isolated negative glands. All lesions showing a lack of EPCAM expression belonged to patients with EPCAM 3′-end deletions. EPCAM IHC is a useful screening tool, with 100% specificity to identify LS patients due to EPCAM 3′-end deletions in MSH2-negative CRC and MSH2-negative colorectal polyps. View Full-Text
Tipus de document
Article
Versió del document
Versió publicada
Llengua
English
Matèries (CDU)
61 - Medicina
616 - Patologia. Medicina clínica. Oncologia
Paraules clau
Còlon -- Càncer
Immunohistoquímica
Pòlips (Patologia)
Tumors
Mutació (Biologia)
Colon -- Cáncer
Inmunohistoquímica
Pólipos (Patología)
Tumores
Mutación (Biología)
Colon cancer
Immunohistochemistry
Polyps (Pathology)
Tumors
Mutation (Biology)
Pàgines
20
Publicat per
MDPI
Col·lecció
12; 10
Publicat a
MDPI
Citació
Cuatrecasas, Míriam; Gorostiaga, Iñigo; Riera, Cristina [et al.]. Complete loss of EPCAM immunoexpression identifies EPCAM deletion carriers in MSH2-negative colorectal neoplasia. Cancers, 2020, 12(10), p. 1-20. Disponible en: <https://www.mdpi.com/2072-6694/12/10/2803>. Fecha de acceso: 3 nov. 2020. DOI: 10.3390/cancers12102803
Aquest element apareix en la col·lecció o col·leccions següent(s)
- Ciències de la Salut [740]
Drets
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com https://creativecommons.org/licenses/by/4.0/